Brief: Vigil Neuroscience Reports Positive Data From Its Phase 1 Clinical Trial
23/01/2025 12:12
Jan 23 (Reuters) - Vigil Neuroscience Inc VIGL.O :
* VIGIL NEUROSCIENCE REPORTS POSITIVE DATA FROM ITS PHASE 1
CLINICAL TRIAL EVALUATING VG-3927 FOR THE POTENTIAL TREATMENT OF
ALZHEIMER’S DISEASE
* VIGIL NEUROSCIENCE INC - VG-3927 TO ADVANCE TO PHASE 2
TRIAL IN
Q3 2025
* VIGIL NEUROSCIENCE INC - VG-3927 ACHIEVED UP TO 50%
REDUCTION OF
STREM2 IN CSF
* VIGIL NEUROSCIENCE INC - VG-3927 SHOWED FAVORABLE SAFETY
AND
TOLERABILITY PROFILE
Source text: ID:nGNXqgh0d
Further company coverage: VIGL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vigil Neuroscience
See all newsVigil Neuroscience Inc reports results for the quarter ended June 30 - Earnings Summary
Vigil Neuroscience Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP
U.S. RESEARCH ROUNDUP-Ralph Lauren, Vigil Neuroscience, Workday
Deals of the day-Mergers and acquisitions